Stocks Down Under’s Top 10 Hottest ASX Stocks to Look At in 2026!

Today, on the first trading day of 2026, Stocks Down Under publishes its its 10 Hottest ASX Stocks to Look At in the year ahead!

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

Stocks Down Under’s Top 10 Hottest ASX Stocks to Look At in 2026!

Note: These stocks are in no particular order. 

Weebit Nano (ASX:WBT)

Weebit Nano is the most advanced ASX semiconductor stock, having commercialised its ReRAM technology with potential to replace flash memory – read this article for a broader overview of the company and its technology. The key catalyst will be its financial results when we will see whether or not it will have achieved the results it has promised investors (namely $10m in annual revenues for FY26). It was a slow and steady journey, taking roughly 5 years to sign its first licensee (SkyWater) and another couple of sign its second…but now it has 4 foundries/IDMs and 3 product companies. The most recent company to sign on the dotted line is Texas Instruments (TI, NASDAQ:TXN), the world’s largest analog semiconductor manufacturer.

Aussie Broadband (ASX:ABB)

Aussie Broadband stands out amongst its peers in the telco space for its reputation for customer service. Case in point: This author has never heard another CEO say the words ‘no bullshit’ as former boss Philip Britt did during this author’s time at Stockhead. It has been non-stop growth ever since it listed – even if growth briefly slowed at times. But in FY25, the company grew its revenues 19% to $1.2bn and it made a $55.8m profit off the back of 778,400 total connections (up 15%). For FY26 guidance, the company has provided an underlying EBITDA range of approximately $157 million to $167 million, implying growth of about 14 % to 21 % compared to FY25.

EBR Systems (ASX:EBR)

EBR’s WiSE system (Wireless Stimulation Endocardially) uses wireless technology to deliver pacing stimulation directly to the inside of the left ventricle of the heart, thus preventing heart failure. 2025 was the year it gained FDA approval and was implanted into the first patients. A stronger push for sales growth will come in 2026, once the company has expanded its sales team. There is already a US$4bn+ market awaiting that could only get bigger over time. One key development that occurred to end the year was the first implant of WiSE as part of a clinical trial aiming to see if it could act complementary to Abbott’s right ventricle pacemaker.

Sandfire (ASX:SFR)

Part of our thesis for this one is that copper will be the commodity of 2026, due to the Copper Crunch getting worse and worse. Demand is growing and growing, but supply is lagging. Copper is fundamental for many modern technologies like solar panels, wind turbines, EVs, AI and data centres not even counting more established technologies like air conditioners, refrigerators, smart phones and lighting. To illustrate how important copper is, the average ‘copper accumulated stock-in-use per capita’ is 100kg – essentially the total amount of copper in everything a typical household uses.

But the other half of our thesis is that we think this is the best copper play on the ASX. Key to this company is its MATSA mine in Spain that produced over 150kt in FY25. The company expects this figure again in FY26, even if only 2% growth, along with developments at earlier-stage projects including a PFS for Black Butte inthe USA along with a maiden reserve at A1 (part of the Motheo project in Botswana) by the end of the financial year.

Propel Funeral Partners (ASX:PFP)

Death is one of life’s certainties and PFP has been the only stock with exposure to it since Invocare departed the bourse. Its full year result for FY25 was $225.8m revenue (up 8%, ahead of guidance and purportedly a company record) and a $21.6m profit (up 2.2%). It paid 14.4c per share in dividends and closed the period with $143m in available funding. 22,602 funerals were performed (up 4.4%) and its average revenue per funeral was $6,721.

While no guidance has been given for FY26, as death volumes do fluctuate – death volumes in Australia are set to continue to grow in the years ahead. if you wanted to value Propel on a takeover basis, it would be worth $6.66, nearly 30% higher than right now. This is using a P/E multiple of 37x, the implied takeover multiple of Invocare.

IPD Group (ASX:IPD)

At its core, IPD provides electricity services and infrastructure. Its flagship brand IPD is a distributor of electrical equipment, such as distribution boards, switchboard systems and power meters. It has a few other brands, one of which is Addelec, a provider of engineering services with EV charging infrastructure specialisation. And one recent acquisition (i.e. last week) was Platinum Cables, which supplies power and communication cables to Australian miners.

Australian power consumption keeps going up in conjunction with population growth and adoption of new technologies, from EVs to data centres. Although the average energy use per person can fluctuate annually, the country’s total generation and consumption are only going in one direction – up.  Because of rising energy usage (and costs), infrastructure operators are upgrading their assets and putting more effort into proactive maintenance to avoid the costs of potential malfunctions. This is why investors should be excited about it.

EOS (ASX:EOS)

EOS is now a $1.8bn company. Now part of it could be due to investors fleeing Droneshield (ASX:DRO) in light of that company’s executives selling tens of millions of dollars in shares and wanting exposure to defence tech. EOS has actually been around multiple decades and actually began through the privitisation of part of the Australian government’s space activities.

But today as built up operations in Australia, the U.S., Singapore, the Middle East, Germany, and the Netherlands. And an August 2025 announcement of the world’s first export of a 100 kW laser anti-drone weapon system to an undisclosed NATO European country, catalysed a surge in the share price—rising over 40% on the announcement alone and now sitting at $1.8bn.

Objective Corporation (ASX:OCL)

Objective Corporation has software products that can handle common problems or manually intensive tasks local governments and businesses in highly regulated sectors undertake on a daily basis as well as to store data. This software increases the ease, security and efficiency with which such tasks can be accomplished. Since listing, the company has not raised a cent of capital because it has been consistently profitable. It remains majority owned by founder Tony Wall. 

During FY25 Objective Corporation reported group revenue of $123.5 million, up 5%, and a $35.4m profit (up 13%). The company is explicitly targeting around 15 % growth in annualised recurring revenue (ARR) in FY26, building on its momentum from FY25. Management has also indicated that it expects profit growth above the ARR growth rate for the coming year, underpinned by recurring revenue strength, ongoing innovation (especially through AI-enabled product enhancements), and opportunities in public sector markets globally.

Australian Ethical (ASX:AEF)

AEF is is an ethical wealth manager, offering superannuation, pension and investment funds – predominantly equities and fixed income. Whether or not you like the growing social progressivism amongst younger generations – and even amongst some Boomers; it is turning out to be a windfall for AEF. Consider that AEF began in the 1980s but only surpassed $1bn FUM in 2014. Now it has ~$14bn and this figure keeps growing and growing.

BlinkLab (ASX:BB1)

While no one at Stocks Down Under has a direct financial interest of any kind, this author would like to disclose having a personal interest in the form of suffering from the problems that this company is trying to fix and is an admirer for that reason. Of course it’d be of little use if the company just had an idea and/or non-binding MoUs, but this company has done well.

BlinkLab has an e-platform that can help diagnose neurological disorders in children such as ADHD and autism. This is not a subjective test that costs thousands of dollars and is only one doctor’s opinion – this is a definitive conclusion that will cost a lot less. The test makes a judgement by biomarker detections, evaluating brain function, computer vision and facial reflexes in response to visual and auditory stimuli – stuff you cannot fake.

The company aims to conduct a clinical trial to obtain FDA approval, followed by CE Mark approval in Europe – 2026 will be the year the trial happens and the green light could occur by the year’s end.

Disclosure: Stocks Down Under directors own shares in Weebit and Weebit is a research client of Pitt Street Research.